Skip to main content
SpringerLink
Log in

Reassessment of digoxin and other low-dose positive inotropes in the treatment of chronic heart failure

  • State-Of-The-Art Lectures
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

Digoxin and other low doses of drugs that have inotropic properties may have an important role to play in the therapy of patients with chronic heart failure. There is convincing evidence that digoxin is effective in relieving the signs and symptoms of heart failure due to systolic dysfunction. While earlier results with some of the other agents have been disappointing, recent data suggest that a reevaluation of these agents is necessary. There is now compelling evidence that lower doses of these agents may be clinically useful without necessarily having any significant hemodynamic effects. The recent experience with vesnarinone is especially promising in showing that therapy with these agents may improve survival in addition to improving clinical status. It is becoming recognized that hemodynamic activity should not necessarily be a prerequisite for clinical utility for these agents. The neuroendocrine and electrophysiologic effects of many of these agents, including digitalis, remain incompletely characterized and may play an important role in their therapeutic benefit. It appears that certain drugs that have inotropic properties may be effective only when their inotropic effects are not readily demonstrated. Further research into the appropriate mechanisms of action and proper dosing of these drugs may lead to a renewed interest in the use of positive inotropes for chronic heart failure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Yusuf S, Thom T, Abbott RD. Changes in hypertension treatment in congestive heart failure mortality in the United States.Hypertension 1989;12:174–179.

    Google Scholar 

  2. National Center for Health Statistics.Vital Statistics of the United States, 1988. Vol II. Mortality, Part A. Washington, DC: Public Health Service, DHHS publication no. (PHS), 1991:91–1101.

    Google Scholar 

  3. Schocken DD, Arrieta MI, Leaverton PE. Prevalence in mortality rate of congestive heart failure in the United States.J Am Coll Cardiol 1992;20:301–306.

    Google Scholar 

  4. Ho KKL, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects.Circulation 1993;88:107–115.

    Google Scholar 

  5. Parmley WW. Pathophysiology of congestive heart failure.Clin Cardiol 1992;15:(Suppl I):I5-I12.

    Google Scholar 

  6. Douglas PS, Morrow R, Loli A, Reichek N. Left ventricular shape, afterload and survival in idiopathic dilated cardiomyopathy.J Am Coll Cardiol 1989;13:311–315.

    Google Scholar 

  7. Franz MR, Cima R, Wang D, Profitt D, Kurt R. Electrophysiological effects of myocardial stretch and mechanical determinants of strech-activated arrhythmias.Circulation 1992;86:968–978.

    Google Scholar 

  8. Packer M. The search for the ideal inotropic agent [editorial].N Engl J Med 1993;329:201–202.

    Google Scholar 

  9. Katz AM. Biochemical “defect” in the hypertrophied and failing heart: Deleterious or compensatory.Circulation 1973;47:1076–1079.

    Google Scholar 

  10. Bonow RO, Dilsizian V. Thallium-201 for assessing myocardial viability.Semin Nucl Med 1991;21:230–241.

    Google Scholar 

  11. Marban E, Koretsune Y, Correti M, Chacko VP, Kusuoka H. Calcium and its role in myocardial cell injury during ischemia and reperfusion.Circulation 1989;80(Suppl IV):IV17-IV22.

    Google Scholar 

  12. Yusuf S. Clinical experience in protecting the failing heart.Clin Cardiol 1993;16(Suppl):II25-II29.

    Google Scholar 

  13. Withering W. An account of the foxglove and some of its medical uses with practical remarks on dropsy and other diseases. In: Willins FA, Keyes TE, eds.Classics of Cardiology. New York: Henry Schuman, 1941:231–252.

    Google Scholar 

  14. Fozzard HA, Sheets MF. Cellular mechanism of action of cardiac glycosides.J Am Coll Cardiol 1985;5:10A-15A.

    Google Scholar 

  15. Feldman MD, Copelas L, Gwathmey JK, et al. Deficient production of cyclic AMP: Pharmacologic evidence of an important cause of contractile dysfunction in patients with endstage heart failure.Circulation 1987;75:331–339.

    Google Scholar 

  16. Ferguson DW. Digitalis and neurohormonal abnormalities in heart failure and implications for therapy.Am J Cardiol 1992;69:24G-33G.

    Google Scholar 

  17. Gheorghiade M, Ferguson DW. Digoxin: A neurohormonal modulator in heart failure?Circulation 1991;84:2181–2186.

    Google Scholar 

  18. Van Veldhuisen DJ, Man in't Veld AJ, Dunselman PHJM, et al. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: Results of the Dutch Ibopamine Multicenter Trial (DIMT).J Am Coll Cardiol 1993;22:1564–73.

    Google Scholar 

  19. Ribner HS, Plucinski DA, Hsieh AM, et al. Acute effects of digoxin on total systemic vascular resistance in congestive heart failure due to dilated cardiomyopathy: A hemodynamic-hormonal study.Am J Cardiol 1985;56:896–904.

    Google Scholar 

  20. Ribner HS, Zucker MJ, Stasior C, Talentoski D, Standicki R, Lesch M. Vasodilators as first-line therapy for congestive heart failure: A comparative hemodynamic study of hydralazine, digoxin, and their combination.Am Heart J 1987;114:91–96.

    Google Scholar 

  21. Gheorghiade M, Hall V, Lakier J, Goldstein S. Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure.J Am Coll Cardiol 1989;13:134–142.

    Google Scholar 

  22. Tauke J, Gheorghiade M. Acute hemodynamic effects of digitalis.Herz 1993;18:86–94.

    Google Scholar 

  23. Ross Jr. S, Waldhausen JA, Braunwald E. Studies on digitalis I. Direct effects on peripheral vascular resistance.J Clin Invest 1960;39:930–936.

    Google Scholar 

  24. Williams Sr. JF, Potter RD. The effect of chronic digitoxin administration on the contractile state of normal and nonfailing hypertrophied myocardium.J Clin Invest 1975;56:71–78.

    Google Scholar 

  25. Williams MH, Zohman LR, Ratner AC. Hemodynamic effects of cardiac glycosides on normal human subjects during rest and exercise.J Appl Physiol 1958;13:417–421.

    Google Scholar 

  26. Gheorghiade M, St. Clair J, St. Clair C, Beller GA. Hemodynamic effects on intravenous digoxin in patients with severe heart failure initially treated with diuretics and vasodilators.J Am Coll Cardiol 1987;9:849–857.

    Google Scholar 

  27. Arnold SR, Byrd RC, Meister W, et al. Long-term digitalis therapy improves left ventricular function in heart failure.N Engl J Med 1980;303:1443–1448.

    Google Scholar 

  28. Schmidt TA, Allen PD, Colucci WS, Marsh JD, Kyeldsen K. No adaptation to digitalization as evaluated by digitalis receptor (Na, K-ATPase). Quantification in explanted hearts from donors without heart disease and from digitalized recipients with end-stage heart failure.Am J Cardiol 1992;70:110–114.

    Google Scholar 

  29. Beller GA, Smith TW, Abelman WH, Haber E, Hood WB. Digitalis intoxication: A prospective clinical study with serum level correlations.N Engl J Med 1971;284:989–997.

    Google Scholar 

  30. Rodensky PL, Wasserman F. Observations on digitalis intoxication.Arch Intern Med 1961;108:171–188.

    Google Scholar 

  31. Starr J, Luchi RJ. Blind study on the action of digitoxin on elderly women.Am Heart J 1969;78:740–751.

    Google Scholar 

  32. Kirsten E, Rodstein M, Iuster Z. Digoxin in the aged.Geriatrics 1973;(Suppl I):95–101.

    Google Scholar 

  33. Dobbs SM, Kenyon WI, Dobbs RJ. Maintenance digoxin after an episode of heart failure: Placebo-controlled trial in outpatients.Br Med J 1977;1:749–752.

    Google Scholar 

  34. Lee C, Johnson RA, Bingham JB. Heart failure in outpatients.N Engl J Med 1982;306:699–705.

    Google Scholar 

  35. Fleg JL, Gottlieb SH, Lakatta EG. Is digoxin really important in treatment of compensated heart failure?Am J Med 1982;73:244–250.

    Google Scholar 

  36. Taggart AJ, Johnson GC, McDevitt DG. Digoxin withdrawal after cardiac failure in patients with sinus rhythm.J Cardiovasc Pharmacol 1983;5:229–234.

    Google Scholar 

  37. Guyatt GH, Sullivan MJ, Fallen EL, et al. A controlled trial of digoxin in congestive heart failure.Am J Cardiol 1988;61:371–375.

    Google Scholar 

  38. Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure.JAMA 1988;259:539–544.

    Google Scholar 

  39. The German and Austrian Xamoterol Study Group. Double blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure.Lancet 1988;i:489–493.

    Google Scholar 

  40. DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R, for the Milrinone Multicenter Trial Group. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure.N Engl J Med 1989;320:677–683.

    Google Scholar 

  41. Pugh SE, White NJ, Aronson JK, Grahame-Smith DG, Bloomfield JG. Clinical, hemodynamic, and pharmacologic effects of withdrawal and reintroduction of digoxin in patients with heart failure in sinus rhythm after long term treatment.Br Heart J 1989;61:529–539.

    Google Scholar 

  42. Fleg JL, Rothfield B, Gottlieb SH, Wright J. Effect of maintenance digoxin therapy on aerobic performance and exercise left ventricular function in mild to moderate heart failure due to coronary artery disease: A randomized, placebo, controlled crossover trial.J Am Coll Cardiol 1991;17:743–757.

    Google Scholar 

  43. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK, on behalf of the PROVED Investigative Group. Multicenter, double blind, placebo controlled randomized withdrawal trial of the efficacy and safety of digoxin in patients with mild to moderate chronic heart failure not treated with converting enzyme inhibitors.J Am Coll Cardiol 1993;22:955–962.

    Google Scholar 

  44. Packer M, Gheorghiade M, Young JB, et al. for the RADIANCE Study Group. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors.N Engl J Med 1993;329:1–7.

    Google Scholar 

  45. Drexler H, Schumacher M, Siegrist J, Just H, for the CADS Multicenter Study Group. Effect of captopril and digoxin on quality of life and clinical symptoms in patients with coronary artery disease and mild heart failure.J Am Coll Cardiol 1992;19:260A.

    Google Scholar 

  46. Kraus F, Rudolph C, Rudolph W. Effectivity of digitalis in patients with chronic heart failure and sinus rhythm: An overview of randomized, double-blind, placebo-controlled studies.Herz 1993;18:95–117.

    Google Scholar 

  47. Brouwer J, Van Veldhuisen DJ, Man in't Veld AJ, Haaksma J, Viersma JW, for the DIMT Study Group. Relation between heart rate variability and neurohumoral status in patients with heart failure. Effects of neurohumoral modulation by digoxin and ibopamine (abstr).Circulation 1993;88:I108.

    Google Scholar 

  48. Yusuf, Garg R, Held P, Gorlin R. Need for a large randomized trial to evaluate the effects of digitalis on morbidity and mortality in congestive heart failure.Am J Cardiol 1992;69:64G-70G.

    Google Scholar 

  49. Packer M. The development of positive inotropic agents for chronic heart failure: How have we gone astray?J Am Coll Cardiol 1993;22(Suppl A):119A-126A.

    Google Scholar 

  50. Rajfer SI, Aaron AH, Rossen JD, Goldberg LI. Beneficial hemodynamic effects of oral levodopa in heart failure.N Engl J Med 1984;310:1357–1362.

    Google Scholar 

  51. Colucci WS, Alexander RW, Williams GH, et al. Decreased lymphocyte beta-adrenergic receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol.N Engl J Med 1981;305:185–190.

    Google Scholar 

  52. Dies F, Krell NJ, Witlow P, et al. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure (abstr).Circulation 1986;74(Suppl II):II39.

    Google Scholar 

  53. The German and Austrian Xamoterol Study Group. Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure.Lancet 1988;1:49–93.

    Google Scholar 

  54. Pouleur H, Van Eyll C, Hanet C, Cheron P, Charlier AA, Rousseau MF. Long-term effect of xamoterol on left ventricular diastolic function and late remodeling: A study in patients with anterior myocardial infarction and single-vessel disease.Circulation 1988;77:1081–1089.

    Google Scholar 

  55. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure.Lancet 1990;336:1–6.

    Google Scholar 

  56. Henwood JM, Todd PA. Ibopamine: A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.Drugs 1988;36:11–31.

    Google Scholar 

  57. Rousseau MF, Raigoso J, Van Eyll C, et al. Effects of intravenous epinine administration on left ventricular systolic performance, coronary hemodynamics, and circulating catecholamines in patients with heart failure.J Cardiovasc Pharmacol 1992;19:155–162.

    Google Scholar 

  58. Simonton CA, Chatterjee K, Cody RJ, et al. Milrinone in congestive heart failure: Acute and chronic hemodynamic and clinical evaluation.J Am Coll Cardiol 1985;6:453–459.

    Google Scholar 

  59. Massie B, Bourassa M, DiBianco R, et al., for the Amrinone Multicenter Trial Group. Long-term oral administration of amrinone for congestive heart failure: Lack of efficacy in a multicenter controlled trial.Circulation 1985;71:963–971.

    Google Scholar 

  60. Packer M, Carver JR, Rodenheffer RJ, et al. Effective of oral milrinone on mortality and severe chronic heart failure.N Engl J Med 1991;325:1468–75.

    Google Scholar 

  61. Kukin ML, Massie BM, Hendrix GH, et al., on behalf of the PROMISE Study. Characterization of the proarrhythmic effects of oral milrinone in severe heart failure: The PROMISE Study (abstr).J Am Coll Cardiol 1992;19(Suppl):260A.

    Google Scholar 

  62. DiBianco R, Shabetai R, Kostuk W, et al. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with congestive heart failure.N Engl J Med 1989;321:677–683.

    Google Scholar 

  63. Colucci WS, Sonnenblick EH, Adams KF, et al. Efficacy of phosphodiesterase inhibition with milrinone in combination with converting enzyme inhibitors in patients with heart failure.J Am Coll Cardiol 1993;22(Suppl A):113A-118A.

    Google Scholar 

  64. Jain P, Brown Jr. EJ, Langenbacke G, et al. Effects of milrinone on left ventricular remodeling after acute myocardial infarction.Circulation 1991;84:796–804.

    Google Scholar 

  65. Sweet CS, Ludden CT, Stabilito I, et al. Beneficial effects of milrinone and enalapril on long-term survival of rats with healed myocardial infarction.Eur J Pharmacol 1988;147:29–37.

    Google Scholar 

  66. Weishaar RE, Kobylarz-Singer DC, Stephen RP, Kaplan HR. Subclasses of cyclic AMP specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility.Circ Res 1987;61:539–47.

    Google Scholar 

  67. Lee JC, Downing SE. Cyclic AMP and the pathogenesis of myocardial injury.Res Commun Chem Pathol Pharmacol 1971;23:200–204.

    Google Scholar 

  68. Uretsky BF, Jessup M, Constam MA, et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure: Lack of benefit compared with placebo.Circulation 1990;82:774–80.

    Google Scholar 

  69. Narahara KA and the Western Enoximone Study Group. Enoximone versus placebo: A double-blind trial in chronic congestive heart failure (abstr).Circulation 1989;80(Suppl):II175.

    Google Scholar 

  70. Goldberg AD, Nicklas J, Goldstein S, et al., for the Imazodan Research Group. Effectiveness of imazodan for treatment of chronic congestive heart failure.Am J Cardiol 1991;68:631–636.

    Google Scholar 

  71. Kubo SH, Gallob S, Bourg ER, et al., for the Pimobendan Multicenter Research Group. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure: Results of a multicenter trial.Circulation 1992;85:942–949.

    Google Scholar 

  72. Feldman AM, Bristow MR, Parmley WW, et al., for the Vesnarinone Study Group. Effects of vesnarinone on morbidity and mortality in patients with heart failure.N Engl J Med 1993;329:149–155.

    Google Scholar 

  73. Kubo SH, Rector TS, Strobeck GE, Cohn JN. OPC-8212 in the treatment of congestive heart failure: Results of a pilot study.Cardiovasc Drugs Ther 1988;2:653–660.

    Google Scholar 

  74. Sasayama S, Inoue M, Asanoi H, et al. Acute hemodynamic effects of a new inotropic agent, OPC-8212, on severe congestive heart failure.Heart Vessels 1986;2:23–28.

    Google Scholar 

  75. Feldman AM, Strobeck JE. Clinical and preclinical evaluation of the investigational inotropic agent, vesnarinone.Heart Failure 1993;9:156–164.

    Google Scholar 

  76. Mahdyoon H, Battilana G, Rosman H, Goldstein S, Gheorghiade M. The evolving pattern of digoxin intoxication: Observations at a large urban hospital from 1980–1988.Am Heart J 1990;120:1189–1194.

    Google Scholar 

  77. Gheorghiade M, Zarowitz B. Review of randomized trials of digoxin therapy in patients with chronic heart failure.Am J Cardiol 1992;69:48G-63G.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Northwestern University Medical School, 250 E. Superior, Wesley 524, 60611, Chicago, IL, USA

    Jason Tauke, Diana Han & Mihai Gheorghiade MD

Authors
  1. Jason Tauke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Diana Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mihai Gheorghiade MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tauke, J., Han, D. & Gheorghiade, M. Reassessment of digoxin and other low-dose positive inotropes in the treatment of chronic heart failure. Cardiovasc Drug Ther 8, 761–768 (1994). https://doi.org/10.1007/BF00877124

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00877124

Key Words

Search

Navigation